Regumate Equine
Active substance
ATC code
Species
Horses (mares).
Indications
In mares with significant follicular activity during the transitional period between seasonal anoestrus and the breeding season (follicles of at least 20-25 mm present at the beginning of treatment):
• Suppression/prevention of oestrus (usually after 1 to 3 days of treatment) during the prolonged oestrus periods occurring during this period.
• Control of the time of initiation of oestrus (approximately 90% of mares show signs of oestrus within 5 days following the end of treatment) and synchronisation of ovulation (60% of mares ovulate between days 11 and 14 following the end of treatment).
Dose to be administered and administration route
Oral use.
0.044 mg altrenogest per kg bodyweight per day, for 10 consecutive days.
Carefully withdraw the volume of veterinary medicinal product corresponding to the mare bodyweight (1 ml per 50 kg bodyweight) and administer this volume via oral route.
- 150, 300 and 1000 ml bottles: Wearing gloves remove the original cap and in its place screw on the luer lock cap. Keeping the bottle upright, screw the syringe onto the luer lock cap orifice, turn the bottle upside down, and carefully withdraw the solution from the bottle using the syringe.
Turn the bottle right way up before detaching the syringe. Securely replace the small cap on the luer lock cap.
- 250 ml bottles: Remove the white cap and the aluminium foil seal from the neck of the measuring compartment. Keeping the bottle upright, press the body of the bottle until the required volume of veterinary medicinal product is accumulated into the measuring compartment. Carefully pour the content of the measuring compartment on the mare feed.
The veterinary medicinal product should be added to the mare’s feed, at a single feeding per day, or directly administered into the mouth using a syringe. Avoid introduction of contamination.
Adverse reactions
Horses (mares):
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Uterine infection |
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.